Sign In
Buy PDS
$95.01
+1.95 (+2.10%)
At Close: Jun 03, 2026
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
08:00am, Wednesday, 07'th May 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Precision Drilling Corporation (PDS) Q1 2025 Earnings Call Transcript
09:25pm, Thursday, 24'th Apr 2025
Precision Drilling Corporation (NYSE:PDS ) Q1 2025 Earnings Conference Call April 24, 2025 1:00 PM ET Company Participants Lavonne Zdunich - Vice President of Investor Relations Carey Ford - Chief Fin
Precision Drilling (PDS) Misses Q1 Earnings and Revenue Estimates
07:45pm, Wednesday, 23'rd Apr 2025
Precision Drilling (PDS) came out with quarterly earnings of $1.53 per share, missing the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.88 per share a year ago.
Precision Drilling Announces 2025 First Quarter Unaudited Financial Results
05:30pm, Wednesday, 23'rd Apr 2025
CALGARY, Alberta, April 23, 2025 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
10:16am, Wednesday, 23'rd Apr 2025
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
Earnings Preview: Precision Drilling (PDS) Q1 Earnings Expected to Decline
11:06am, Wednesday, 16'th Apr 2025
Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
08:00am, Wednesday, 16'th Apr 2025
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Bi
CALGARY, Alberta, April 02, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
07:30am, Thursday, 27'th Mar 2025
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer
Precision Drilling Corporation 2025 First Quarter Results Conference Call and Webcast
04:00pm, Wednesday, 26'th Mar 2025
CALGARY, Alberta, March 26, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 first quarter results after the market closes on Wednesday, April 23, 2025,
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
08:00am, Tuesday, 25'th Mar 2025
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
08:00am, Tuesday, 18'th Mar 2025
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #1
PDS Biotech Leadership to Participate in March Conferences
08:00am, Tuesday, 11'th Mar 2025
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
